2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2470 The separation graft-versus-leukemia from graft-versus-host disease by promoting the reconstitution of CD62L+ B cells in combined unmanipulated haploidentical and cord blood transplantation

Qiong Liu, Guo Qiu2, Ruoyang Shao, MD, PhD3, Xi Xu4, Shengjiao Tang5, Sijian Yu6, Qifa Liu, MD7
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background:
Unmanipulated haploidentical peripheral blood stem cell transplantation combined with umbilical cord blood (haplo-PBSC+UCB) has shown superior clinical outcomes over haplo-PBSC plus bone marrow (haplo-PBSC+BM) in patients with hematological malignancies; however, the underlying immune dynamics remain poorly understood. This study aimed to investigate the immunological mechanisms driving the survival advantage associated with the UCB-based graft.

Methods:
We performed a retrospective analysis of 292 patients who received either haplo-PBSC+UCB (UCB group), haplo-PBSC+BM (BM group), or HLA-matched related donor PBSC (PB group). Lymphocyte subset reconstitution was assessed by flow cytometry at 1, 3, and 6 months post-transplantation. To dissect the cellular and molecular basis, we integrated high-resolution single-cell RNA-sequencing with clinical cohort data, and further performed trajectory analysis, regulatory network inference, interactome modeling, and functional validation assays (including T-cell expansion and IFN-γ release experiments).

Results:
B cells reconstituted more rapidly in the UCB group, and this faster recovery significantly correlated with lower relapse rates and improved overall and relapse-free survival. Single-cell and cohort analyses revealed that the survival benefit was closely linked to dynamic remodeling of the post-transplant immune ecosystem, driven by selective expansion of a distinct SELL-high (CD62L?) memory-like B-cell subset. Trajectory and regulatory network analyses showed that these B cells actively constrained the PRDM1/XBP1-driven terminal plasma cell differentiation program, remaining locked in a professional antigen-presenting state through sustained IRF8 upregulation. Interactome modeling identified this CD62L-high population as a critical orchestrator of B–T cell crosstalk. T cells in UCB grafts were skewed toward effector functions, including enhanced cytotoxicity and helper programs. Functional validation confirmed that CD62L? B cells substantially boosted T-cell expansion and IFN-γ release, thereby promoting graft-versus-leukemia (GVL) effects via enhanced antigen presentation, without increasing graft-versus-host disease.

Conclusions:
This study reveals biased lymphocyte regeneration in the UCB group and identifies CD62L? B cells as both potential prognostic biomarkers and promising therapeutic targets to optimize post-transplantation immune reconstitution and GVL efficacy.

Qiong Liu: No relevant conflicts of interest to declare.